Destiny Pharma Limited

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and...

Anti-microbial resistance,drug development,biotech,and anti-microbials

Destiny pharma limited operates in the Biotechnology research industry.

Destiny pharma limited's revenue is 11m - 100m

Destiny pharma limited has 11 - 50 employees.